Home / Business and Economy / Zydus Lifesciences Secures US FDA Nod for Key BP Medication
Zydus Lifesciences Secures US FDA Nod for Key BP Medication
25 Nov
Summary
- Zydus Lifesciences received US FDA approval for verapamil hydrochloride tablets.
- The drug treats high blood pressure, reducing risks of stroke and heart attack.
- The company's second quarter net profit surged by 39% year-on-year.
Zydus Lifesciences has announced the receipt of final approval from the United States Food and Drug Administration (FDA) for its verapamil hydrochloride extended-release tablets. Available in 120 mg, 180 mg, and 240 mg strengths, this medication is designed to treat high blood pressure and, consequently, reduce the risk of severe cardiovascular incidents such as strokes and heart attacks.
The company's manufacturing facility in Baddi, Himachal Pradesh, will produce the approved tablets. This latest approval adds to Zydus's extensive portfolio, with the group having secured 428 final approvals and filed 487 ANDAs to date. The US market for verapamil hydrochloride extended-release tablets recorded substantial annual sales of $24.5 million, according to recent data.
In financial news, Zydus Lifesciences recently disclosed its second-quarter results, showcasing a robust 39% year-on-year rise in consolidated net profit to ₹1,259 crore. This growth was attributed to healthy business momentum across various geographies and significant foreign exchange gains. Revenue also climbed 17% year-on-year to ₹6,123 crore, with EBITDA surging 38%.
